CD133和B7-H4在非小细胞肺癌中的表达及其临床意义

Expression and clinical significance of CD133 and B7-H4 in non-small cell lung cancer

目的检测CD133和B7-H4在非小细胞肺癌(NSCLC)标本中的表达,并探讨两者的关系及其临床意义。方法采用流式细胞术检测CD133及B7-H4在NSCLC患者胸水中的表达;采用免疫组化SP法检测103例NSCLC手术标本、25例癌旁组织及24例肺部良性病变组织中CD133及B7-H4的表达。结果 CD133和B7-H4在NSCLC胸水中均见表达。肺癌组织CD133表达率49.51%(51/103),B7-H4表达率66.99%(69/103),均高于良性病变组织及癌旁组织(P<0.01)。CD133表达与肿瘤分化程度有关(P<0.01),并且与B7-H4表达相关(P<0.01)。COX回归分析显示CD133阳性表达与NSCLC患者的预后不良有关。结论 CD133与B7-H4在NSCLC中过度表达,可能参与肿瘤逃避宿主的免疫监视过程;CD133可能是NSCLC患者独立的风险因子。

Objective To study the expression and significance of CD133 and B7-H4 in human non-small cell lung cancer （NSCLC）.Methods The expressions of CD133 and B7-H4 were detected by flow cytometry in pleural fluid from NSCLC patients,which were detected with immunohistochemistry in 103 NSCLC specimens,25 tumor-adjacent normal tissues,and 24 benign inflammatory lesion tissues.Results CD133 and B7-H4 expressed in pleural fluid of NSCLC cases.The expression rate of CD133 was 49.51%（51/103） and that of B7-H4 was 66.99%（69/103） in NSCLC specimens,which were all significantly higher than those in tumor-adjacent normal tissues and in benign lesions（P0.01）.CD133 expression was related to the differentiation degree of NSCLC,and correlated with B7-H4 expression（P0.01）.CD133 positive expression was associated with poor prognosis of NSCLC patients.Conclusion CD133 and B7-H4 are overexpressed in NSCLC and might induce the process of tumor evading host immune surveillance.CD133 might be an independent risk factor for NSCLC.